Focused on better outcomes for advanced therapies and biomanufacturing
Currently in the final stages of verification, our soon to be available MUSCLE.SET library of promoters. Developed using Syngensys proprietary computational selection and design tools, these promoters provide broad options for strength of expression and targeting, assessed specifically against HepG2 liver cell lines.
Currently in final validation, our NK.SET promoters and designed to provide a range of expression activity options in natural killer (NK) cells while ensuring minimal activity in CD19 expressing B-Cell derived cancers. Demonstrating Syngensys ability to design specific on/off activity requirements for highly specific cell types and applications.
